FDA Brief: Pemetrexed Injection Receives FDA Approval for Lung Cancer
Posted: Wednesday, September 9, 2020
The U.S. Food and Drug Administration (FDA) recently approved an injectable form of pemetrexed for patients with recurrent or metastatic nonsquamous non–small cell lung cancer with a history of chemotherapy. The drug is indicated as a single-agent treatment after four cycles of first-line platinum-based chemotherapy.
